10323-40-7

Basic information

• Product Name: 2-BROMO-3-METHYLBUTYRIC ACID
• CAS NO: 10323-40-7
• Molecular Formula: C₅H₉BrO₂
• Molecular Weight: 181.03
• Mol File: 10323-40-7.mol
• Article Data: 29

Chemical Properties

• Melting Point: 44°C
• Appearance: /
• Density: 1.4590
• Refractive Index: 1.4930 (estimate)
• CAS DataBase Reference: 2-BROMO-3-METHYLBUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-3-METHYLBUTYRIC ACID(10323-40-7)
• EPA Substance Registry System: 2-BROMO-3-METHYLBUTYRIC ACID(10323-40-7)

Safety Data

• Hazardous Substances Data: 10323-40-7(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-methylbutyric acid is a chemical compound that is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. It is a colorless to yellow liquid with a pungent odor, and has a molecular formula of C5H9BrO2. 2-BROMO-3-METHYLBUTYRIC ACID is primarily used in the production of pharmaceuticals, including sedative and anticonvulsant drugs. It is also used in the manufacturing of fragrance and flavoring compounds. 2-Bromo-3-methylbutyric acid is considered to be a potentially hazardous material and should be handled with care, as it can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 503-74-2 3-methylbutyric acid 
• 64932-36-1 2-bromo-3-methyl-butyraldehyde 
• 10323-40-7 2-bromoisovaleric acid 
• 640-68-6 D-Val-OH 
• 609-12-1 ethyl 2-bromoisovalerate 
• 169320-29-0 (R)-2-bromo-3-methylbutanoic acid (1:1) N-(1-methylethyl)-2-propanamine 
• 161661-13-8 1-<1,2;5,6-di-O-(1-methylethylidene)-α-D-glucofuranosyloxy>-1-trimethylsilyloxy-3-methyl-but-1-ene 
• 139193-62-7 1,2;5,6-di-O-(1-methylethylidene)-α-D-glucofuranosyl 3-methyl butanoate 
• 27109-47-3 2-bromoisovaleryl chloride 
• 167823-33-8 1,2;5,6-di-O-(1-methylethylidene)-α-D-glucofuranosyl-2-bromo-3-methyl butanoate 
• 609-36-9 rac-Pro-OH 
• 590-86-3 isovaleraldehyde 
• 861319-78-0 1-ethoxy-2-bromo-1-chloro-3-methyl-butane 
• 42454-71-7 bromo-isopropyl-malonic acid 

Downstream Products

• 66018-25-5 2-methoxy-3-methylbutanoic acid 
• 541-47-9 3-Methylbutenoic acid 
• 4026-18-0 2-hydroxy-3-methylbutanoic acid 
• 76792-22-8 (R)-2-bromoisovaleric acid 
• 27109-47-3 2-bromoisovaleryl chloride 
• 19866-38-7 α-hydrazino-isovaleric acid 
• 516-06-3 D,L-valine 
• 27109-49-5 (+)-Bromisoval 
• 15206-52-7 N,N-dimethylvaline 
• 80532-76-9 (E)-methyl 2-isopropyl-3-methyl-3-phenyl-2-oxiranecarboxylate 
• 80532-74-7 (E)-2-isopropyl-3-methyl-3-phenyl-2-oxiranecarboxylic acid 
• 80532-73-6 (Z)-2-isopropyl-3-methyl-3-phenyl-2-oxiranecarboxylic acid 
• 140400-37-9 2-((4-chlorophenyl)thio)-3-methylbutanoic acid 
• 63403-43-0 α-(3-methoxy-phenoxy)-isovaleric acid 

Relevant articles and documents

Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible with in Vitro Display

Backbone-cyclic peptides are an attractive class for therapeutic development. However, in vitro display technologies coupled with ribosomal synthesis are intrinsically inapplicable to such "phenotypes" because of loss of the C-terminal peptide region linking to "genotype". Here, we report a methodology enabling the display of backbone-cyclic peptides. To achieve this, genetic code reprogramming was utilized to implement a rearrangement strategy involving the ribosomal incorporation of a designer initiator containing a thiazolidine-protected cysteine and 2-chloroacetoamide (ClAc) side chain, followed by an α-thio acid and cysteine at downstream positions. Upon expression of the linear peptide, spontaneous thioester rearrangement occurs between the α-thioester and the thiol group of the cysteine, liberating the α-thio group and resulting in cross-linking to the upstream ClAc side-chain group. Then selective deprotection of the thiazolidine-protected cysteine immediately promotes intramolecular native chemical ligation, as demonstrated for various sequences and ring sizes. In this approach, the backbone-cyclic peptides retain their C-terminal peptide regions via the side-chain thioether covalent linkage, making them compatible with in vitro display.

Preparation of α-Bromo- and α-Chlorocarboxylic Acids from α-Amino Acids

Diazotization of α-amino acids in 48:52 (w/w) hydrogen fluoride/pyridine along with excess of potassium halide results in the corresponding α-halocarboxylic acids in good to excellent yields (Table 1 and 2).

O-to-S Substitution Enables Dovetailing Conflicting Cyclizability, Polymerizability, and Recyclability: Dithiolactone vs. Dilactone

Developing chemically recyclable polymers represents a greener alternative to landfill and incineration and offers a closed-loop strategy toward a circular materials economy. However, the synthesis of chemically recyclable polymers is still plagued with certain fundamental limitations, including trade-offs between the monomer's cyclizability and polymerizability, as well as between polymer's depolymerizability and properties. Here we describe the subtle O-to-S substitution, dithiolactone monomers derived from abundant feedstock α-amino acids can demonstrate appealing chemical properties different from those of dilactone, including accelerated ring closure, augmented kinetics polymerizability, high depolymerizability and selectivity, and thus constitute a unique class of polythioester materials exhibiting controlled molecular weight (up to 100.5 kDa), atactic yet high crystallinity, structurally diversity, and chemical recyclability. These polythioesters well addresses the formidable challenges of developing chemically recyclable polymers by having an unusual set of desired properties, including easy-to-make monomer from ubiquitous feedstock, and high polymerizability, crystallinity and precise tunability of physicochemical performance, as well as high depolymerizability and selectivity. Computational studies explain why O-to-S modification of polymer backbone enables dovetailing desirable, but conflicting, performance into one polymer structure.

Benzo six-membered nitrogen heterocyclic compound, preparation method and applications

The present invention provides a benzo six-membered nitrogen heterocyclic compound, a preparation method and applications, wherein the benzo six-membered nitrogen heterocyclic compound has a structurerepresented by a formula I or formula II, and can effectively inhibit the bromine domain receptor and effectively inhibit the proliferation of cancer cells. Compared with the existing reported structure types, the compound of the present invention has different binding mode, has high inhibitory activity, can be used as a drug for treating cancer, cell proliferation disorders, inflammatory diseases, autoimmune diseases, septicemia and viral infections, and has good application prospects and high application value.